Rate My Professor Rina Hui

Hui specializes in breast and lung cancers, leading as principal investigator on numerous clinical trials, including phase I studies and landmark phase III trials of immunotherapy and targeted therapies. Her extensive publication record includes over 249 papers with nearly 50,000 citations. Key contributions feature co-authorship on the phase III KEYNOTE-024 trial, detailed in 'Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer' (New England Journal of Medicine, 2016), and patient-reported outcomes from the PACIFIC trial on durvalumab after chemoradiotherapy for stage III non-small-cell lung cancer (Lancet Oncology, 2019). She has influenced the field through membership in the Medical Oncology Group of Australia Expert Group for lung cancer, Breast Cancer Trials, the Thoracic Oncology Group of Australasia, and as a member of the scientific program committees for the European Society for Medical Oncology Congresses in 2021 and 2022. Her work has advanced treatment paradigms in oncology, particularly for thoracic and breast malignancies.